Moleculin Biotech, Inc.

Stage 1 · Basing · week 14→1 today

As of Oct 22, 2026, Moleculin Biotech is in Stage 1, the basing phase, now in its first week (since Oct 22, 2026). It closed at $5.89, 54.7% below its 52-week high and above its 200-day average, which is falling.

Moleculin Biotech, Inc., a late-stage pharmaceutical development company, engages in the development of therapeutic candidates for the treatment of tumors and viruses. More about the company

$5.89

-6.66% today

$6.0M · Micro cap

Market Neutral — Building

Pro read

Pro

Our read

Basing, not in an uptrend yet

Setup score

—

Momentum

Accelerating ⇈

Edge

—

Is MBRX early, or has it already run? Pro answers that for every US stock we cover, after every close.

Get Pro · $19 a month

Renews monthly until you cancel. Cancel any time in Plan & billing.

Loading price chart…

Stage Cycle Timeline2023-08-16 → 2026-10-22

S4 14w

S4 33w

S4 75w

2023-08-162026-10-22

S1S2S3S4Setup score (0–10, dashed line at 5)

S4 14w → S1 7w → S2 4w → S3 6w → S4 33w → S1 6w → S4 75w → S1 8w → S4 13w → S1 1w current

Total tracked: 166 weeks across 10 stage runs.

MBRX among Biotechnology355th of 591 by relative strength

All 591 →

Stocks in Biotechnology ranked by relative strength, with stage and one-month change
#	Stock	Stage	RS	1M
1	GTBPGT Biopharma, Inc.	Stage 2 · wk 7	99	−22.3%
2	IOVAIovance Biotherapeutics, Inc.	Stage 2 · wk 18	99	+38.8%
3	SLSSELLAS Life Sciences Group, Inc.	Stage 3 · wk 4	99	−1.5%
4	MRNAModerna, Inc.	Stage 2 · wk 17	99	+11.3%
5	TWSTTwist Bioscience Corporation	Stage 2 · wk 39	99	−14.5%
6	KODKodiak Sciences Inc	Stage 2 · wk 4	99	+172.1%
7	ERASErasca, Inc.	Stage 3 · wk 5	99	+0.7%
8	CLYMClimb Bio, Inc.	Stage 3 · wk 3	99	−15.8%
…355	MBRXMoleculin Biotech, Inc.	Stage 1 · wk 1	23	+1015.5%

vs 52W High

-54.7%

$0.28 lo$13.00 hi

54.7% below 52W high

Stock is basing below old highs. A volume-backed breakout to new highs would be the Stage 2 signal to watch.

Stage Maturity

Week 1

1w13w26w

Week 1, early base

How long this stock has been basing. Longer bases can produce stronger breakouts, but the breakout itself is the signal.

vs 200 DMA

162.7%

200 DMA: $2.24 · sloping down

Stock is testing its 200 DMA as part of the base. Reclaiming and holding above it is a key Stage 2 prerequisite.

Rel Volume

0.07x

vs 50-day avg

Volume in Stage 1 basing is typically quiet. A surge in volume on an upside breakout is the signal to watch.

Trend Health

↑ ⇈

Short-term trend rising strongly, and accelerating

Two reads of momentum. The arrow shows the direction of the short-term trend: rising (↑ or ↗), flat (→) or rolling over (↓). The ⇈ mark appears when our trend model reads the move as gaining speed on top of the longer trend. Strongest when both agree.

+1015.5%

+177.8%

+131.9%

YTD

+62.7%

-51.0%

Scan Membership

Breakout Watch

Latest: 2024-01-11

4 appearances in last 60 days. First seen: 2020-05-29.

A stock that keeps qualifying week after week does so because its Stage 2 structure keeps holding. Staying power in the scan says more about the trend than any single appearance.

Recent Stage Timeline

2026-10-22S14→1

Wk 1 · Vol 0.07x

2026-10-21S4

Wk 13 · Vol 0.05x

2026-10-20S4

Wk 13 · Vol 0.14x

2026-10-19S4

Wk 13 · Vol 1.15x

2026-10-16S4

Wk 13 · Vol 1.25x

2026-10-15S4

Wk 12 · Vol 0.34x

2026-10-14S4

Wk 12 · Vol 0.27x

2026-10-13S4

Wk 12 · Vol 0.15x

2026-10-12S4

Wk 12 · Vol 0.11x

2026-10-09S4

Wk 12 · Vol 0.21x

2026-10-08S4

Wk 11 · Vol 0.16x

2026-10-07S4

Wk 11 · Vol 0.27x

Moving averages & range

50 DMA

$1.01

200 DMA

$2.24

52W High

$13.00

52W Low

$0.28

5D Low

$0.28

Resistance levels (recent highs)

20d High

$6.31

60d High

$6.31

120d High

$6.31

250d High

$13.00

Next resistance

+7.1%

to 20d High

P/E (TTM)

0.0

Forward -0.1

ROE

-1371.6%

Profit margin 0.0%

Dividend Yield

0.00%

P/B 0.2

Moleculin Biotech: quick answers

What stage is Moleculin Biotech in?

As of Oct 22, 2026, Moleculin Biotech (MBRX) is in Stage 1, the basing phase. It entered Stage 1 on Oct 22, 2026 and is in its first week there. What the four stages mean

Is Moleculin Biotech in an uptrend?

Not yet. Moleculin Biotech is in Stage 1, a base that can come before an uptrend. It trades 162.7% above its 200-day average, which is falling.

How far is Moleculin Biotech from its 52-week high?

Moleculin Biotech closed at $5.89 on Oct 22, 2026, 54.7% below its 52-week high of $13.00. Its 52-week low is $0.28.

How has Moleculin Biotech performed over the past year?

As of Oct 22, 2026, Moleculin Biotech is down 51.0% over the past year and up 62.7% so far in 2026.

Which sector and industry is Moleculin Biotech in?

Moleculin Biotech is in the Biotechnology industry, part of the Health Care sector.

About this companyHealth Care· Biotechnology

Moleculin Biotech, Inc., a late-stage pharmaceutical development company, engages in the development of therapeutic candidates for the treatment of tumors and viruses. Its lead drug candidate is Annamycin, an anthracycline, which is in clinical stage for the treatment of relapsed or refractory acute myeloid leukemia and soft tissue sarcoma lung metastases. The company is also developing WP1066 portfolio, including WP1066, WP1193, and WP1220, which are immune/transcription modulators designed to inhibit phosphorylated signal transducer and activator of transcription for brain tumors and pancreatic and other cancers. In addition, it is developing WP1122 portfolio, such as WP1122, WP1096, and WP1097 designed to exploit the uses of inhibitors of glycolysis comprising 2-deoxy-D-glucose that cut off the energy supply of tumors. The company was incorporated in 2015 and is headquartered in Houston, Texas.

Visit company website →

All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.